Neurovascular Devices – Market Insights – Europe

The European neurovascular device market is poised to experience strong growth through 2034. This growth will be driven by the introduction of newly developed technologies, increasing adoption of innovative devices backed by strong clinical evidence, and a rise in neurovascular procedure volumes due to Europe’s growing elderly population—alongside the urgent and complex nature of these interventions.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for neurovascular devices in Europe from 2019 through 2034.

Adoption of neurovascular thrombectomy devices is rising in Europe due to clinical benefits, innovation, and supportive healthcare policies.

How much market growth is expected in the neurovascular thrombectomy device segment in the European countries?

How will the launch of new technologies in the neurovascular thrombectomy device market influence adoption of thrombectomy for AIS?

What role do ongoing clinical trials play in expanding the use of neurovascular thrombectomy devices?

Companies are releasing new devices and better versions of existing ones to stay ahead in the growing market.

How are established players leveraging next-generation product launches to defend market share and differentiate from emerging competitors?

Which new companies are planning to enter the neurovascular thrombectomy device market in Europe?

What difficulties might these new companies face? Will they be able to take a large share of the market from current players?

What design improvements or clinical features are driving the appeal of upgraded neurovascular devices?

Embolization represents an emerging treatment for chronic subdural hematomas.

What new embolization products and companies are entering this market segment?

Which companies are likely to gain more market share in this space and how?

How strongly are embolization products being adopted for this indication? What is the future adoption outlook?

Which factors affect the decision to choose this emerging treatment?

How will the use of embolization procedures for treating chronic subdural hematoma differ across European countries?

Flow-diverting devices are contributing to growth in the neurovascular embolization device market.

How is innovation in flow-diverting device design fueling broader market acceptance and global procedural growth?

What strategies are companies using to stay ahead in the flow-diverting device market?

What effect will new companies and products have on the European neurovascular device market?